Literature DB >> 7400824

Immune regulation of experimental myasthenia.

S Fuchs, D Bartfeld, Z Eshhar, C Feingold, D Mochly-Rosen, D Novick, M Schwartz, R Tarrab-Hazdai.   

Abstract

Experimental autoimmune myasthenia gravis (EAMG) is an appropriate model for studying the molecular origin, immunological mechanism and regulation of myasthenia gravis. Several approaches are being utilised for the regulation of the immune response to AChR and for immunosuppression of EAMG: Corticosteriods and azathioprine can suppress EAMG concomitantly with suppression of immune responses to AChR. High dose cyclophosphamide treatment in mice facilitates the onset of EAMG and results in a selective suppression of the humoral response to AChR whereas the cellular response is enhanced. Specific immunosuppression of EAMG is achieved by using a nonmyasthenic, denatured AChR preparation which cross reacts with the intact receptor. Various degradations and modifications of AChR are being performed in order to identify the smallest molecular entity responsible for the myasthenic activity of AChR. Studies on specific monoclonal antibodies, anti-idiotypes, and on the effect of measles virus on EAMG are being described and their possible significance in regulating myasthenia are being discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7400824      PMCID: PMC490630          DOI: 10.1136/jnnp.43.7.634

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  34 in total

1.  Benefit from alternate-day prednisone in myasthenia gravis.

Authors:  J R Warmolts; W K Engel
Journal:  N Engl J Med       Date:  1972-01-06       Impact factor: 91.245

2.  Chemical modification of electric eel acetylcholinesterase by tetranitromethane.

Authors:  S Fuchs; D Gurari; I Silman
Journal:  Arch Biochem Biophys       Date:  1974-11       Impact factor: 4.013

3.  Editorial: Infectious (?) myasthenia.

Authors:  S K Datta; R S Schwartz
Journal:  N Engl J Med       Date:  1974-12-12       Impact factor: 91.245

4.  Treatment of myasthenia gravis with prednisone.

Authors:  R B Jenkins
Journal:  Lancet       Date:  1972-04-08       Impact factor: 79.321

5.  Distribution of antibody affinities: technique of measurement.

Authors:  T P Werblin; G W Siskind
Journal:  Immunochemistry       Date:  1972-10

6.  Differential effects of cyclophosphamide on the B and T cell compartments of adult mice.

Authors:  G D Stockman; L R Heim; M A South; J J Trentin
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

7.  Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment.

Authors:  M E Seybold; D B Drachman
Journal:  N Engl J Med       Date:  1974-01-10       Impact factor: 91.245

8.  Measles antibodies in the cerebrospinal fluid of patients with multiple sclerosis.

Authors:  P Brown; F Cathala; D C Gajdusek; C J Gibbs
Journal:  Proc Soc Exp Biol Med       Date:  1971-07

9.  Tetranitromethane. A reagent for the nitration of tyrosyl residues in proteins.

Authors:  M Sokolovsky; J F Riordan; B L Vallee
Journal:  Biochemistry       Date:  1966-11       Impact factor: 3.162

10.  Subacute sclerosing panencephalitis: isolation of measles virus from a brain biopsy.

Authors:  L Horta-Barbosa; D A Fuccillo; J L Sever; W Zeman
Journal:  Nature       Date:  1969-03-08       Impact factor: 49.962

View more
  1 in total

Review 1.  Idiotypes and autoimmunity.

Authors:  I M Roitt; D K Male; A Cooke; P M Lydyard
Journal:  Springer Semin Immunopathol       Date:  1983
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.